| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/20/2013 | US8512752 Hyaluronic acid derivatives obtained via “click chemistry” crosslinking |
| 08/20/2013 | US8512751 Controlled extended release of serotonin receptor anatagonist; alleviating sleep apnea; kits |
| 08/20/2013 | US8512745 Ulipristal acetate tablets |
| 08/20/2013 | US8512744 Sustained release micropellets and process for producing the same |
| 08/20/2013 | US8512738 Biodegradable intravitreal tyrosine kinase implants |
| 08/20/2013 | US8512723 Decontamination of vegetables, meats or fruits by disinfection of such with antimicrobial solution containing lipid and enhancer such as bacteriocins, sugars and enzymes |
| 08/20/2013 | US8512719 Oat extracts: refining, compositions and methods of use |
| 08/20/2013 | US8512718 Pharmaceutical composition for topical application |
| 08/20/2013 | US8512717 A therapeutic component such as quinoxaline derivative, an ophthalmically acceptable carrier component, a retention component; an increased penetration of the therapeutic component through the cornea and into the eye |
| 08/20/2013 | US8512687 Oil in water emulsion comprising NSAIDs and quaternary ammonium halides |
| 08/20/2013 | US8512680 Injectables in foam, new pharmaceutical applications |
| 08/20/2013 | CA2751495C Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof |
| 08/20/2013 | CA2738214C Chewing gum containing low dose amounts of water soluble vitamins |
| 08/20/2013 | CA2736281C Tri-substituted pyrimidine compounds and their use as pde10 inhibitors |
| 08/20/2013 | CA2735107C Co-precipitated salts of fatty acids |
| 08/20/2013 | CA2723302C Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| 08/20/2013 | CA2698825C Deuterated 4 -oxoquinoline derivatives for the treatment of hiv infection |
| 08/20/2013 | CA2651451C Extended release oral multimicroparticle dosage form |
| 08/20/2013 | CA2641310C Igf-ir antagonists as adjuvants for treatment of prostate cancer |
| 08/20/2013 | CA2634232C Method of producing solid preparation disintegrating in the oral cavity |
| 08/20/2013 | CA2608214C Quinoline derivatives as ep4 antagonists |
| 08/20/2013 | CA2606262C Novel histamine h3-receptor ligands and their therapeutic applications |
| 08/20/2013 | CA2602445C Metabolites for nk-i antagonists for emesis |
| 08/20/2013 | CA2589497C Novel specific caspase-10 inhibitors |
| 08/20/2013 | CA2587924C Oral compositions for absorption of phosphorus compounds |
| 08/20/2013 | CA2584170C Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases |
| 08/20/2013 | CA2579378C Treatment of diseases using nalmefene and its analogs |
| 08/20/2013 | CA2569729C Peptidomimetic inhibitors of retroviral proteases and their use as antivirals |
| 08/20/2013 | CA2559036C 9-substituted 8-oxoadenine compound |
| 08/20/2013 | CA2545503C Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases |
| 08/20/2013 | CA2545219C Efficient introduction of an aerosol into a ventilator circuit |
| 08/20/2013 | CA2530660C Combinations of vasoprotective agents and formulations containing them |
| 08/20/2013 | CA2516563C Methods of preventing, treating and diagnosing disorders of protein aggregation |
| 08/20/2013 | CA2515631C 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure |
| 08/20/2013 | CA2499390C Kits and methods for assessing skin health |
| 08/20/2013 | CA2398723C Pharmaceutical composition comprising carriers for products based on vitamin-e, papain and hyaluronidase |
| 08/19/2013 | CA2827869A1 Therapeutic agent for corneal sensory nerve damage containing semaphorin inhibitor as active ingredient |
| 08/15/2013 | WO2013120104A2 Modulators of methyl modifying enzymes, compositions and uses thereof |
| 08/15/2013 | WO2013120095A1 Near-infrared enhancement of circadian and ultradian spatiotemporal cellular coordination in the human integumentary system |
| 08/15/2013 | WO2013120086A1 Inhibition of the glycine cleavage system for treatment of cancer |
| 08/15/2013 | WO2013120081A1 1h- pyrrolo [2, 3 -b] pyridine derivatives and their use as radical quenchers |
| 08/15/2013 | WO2013120078A1 Methods and compositions for treating pain |
| 08/15/2013 | WO2013120045A1 Substituted 1h-indazol-1-ol analogs as inhibitors of beta catenin/tcf protein-protein interactions |
| 08/15/2013 | WO2013119988A1 Pharmaceutical compositions to reduce complications of ocular steroid |
| 08/15/2013 | WO2013119957A1 Weight reduction through inactivation of gastric orexigenic mediator producing cells |
| 08/15/2013 | WO2013119954A1 Induction of highly specific antibodies to a hapten but not to a carrier peptide by immunization |
| 08/15/2013 | WO2013119946A1 Long chain base sphingosine kinase inhibitors |
| 08/15/2013 | WO2013119931A1 Modulators of exchange proteins directly activated by camp (epacs) |
| 08/15/2013 | WO2013119923A1 Different states of cancer stem cells |
| 08/15/2013 | WO2013119917A1 Materials and methods for treating diarrhea |
| 08/15/2013 | WO2013119916A2 Compounds for treating spinal muscular atrophy |
| 08/15/2013 | WO2013119910A1 Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder |
| 08/15/2013 | WO2013119886A1 One pot process for producing 6-hydroxyl nal-opiate |
| 08/15/2013 | WO2013119870A1 Compositions and methods for treatment of peripheral vascular disease |
| 08/15/2013 | WO2013119864A1 Increasing taxane sensitivity in cancer cells |
| 08/15/2013 | WO2013119809A1 Biomarkers for hematologic malignacies |
| 08/15/2013 | WO2013119794A1 Modified release formulations of viloxazine |
| 08/15/2013 | WO2013119791A1 Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use |
| 08/15/2013 | WO2013119774A1 3-(2-amino-ethyl)-alkylidene)-thiazolidine-2,4-dione and 1-(2-amino-ethyl)-alkylidene-1,3-dihydro-indol-2-one derivatives as selective sphingosine kinase 2 inhibitors |
| 08/15/2013 | WO2013119760A1 Multi-layer nicotine-containing pharmaceutical composition |
| 08/15/2013 | WO2013119710A1 Antiviral compound and cox-2 inhibitor combination therapy for functional somatic syndromes, including combination of famciclovir and celecoxib |
| 08/15/2013 | WO2013119677A1 Pharmaceutical compositions containing dimethyl fumarate |
| 08/15/2013 | WO2013119639A1 Substituted prolines / piperidines as orexin receptor antagonists |
| 08/15/2013 | WO2013119605A1 Promoting sleep using at1 receptor blockers |
| 08/15/2013 | WO2013119542A1 Compounds for the treatment of hepatitis c |
| 08/15/2013 | WO2013119518A1 Small molecules for islet expansion |
| 08/15/2013 | WO2013119499A1 Novel compounds for the treatment of hepatitis c |
| 08/15/2013 | WO2013119466A1 Rapidly disintegrating coated tablets |
| 08/15/2013 | WO2013119442A1 Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof |
| 08/15/2013 | WO2013119061A1 Method for manufacturing transdermally delivered hyaluronic acid-protein conjugate and transdermally delivered hyaluronic acid-protein conjugate manufactured using same |
| 08/15/2013 | WO2013119059A1 Injectable composition containing phosphatidylcholine devoid of sodium deoxycholate and preparing method thereof |
| 08/15/2013 | WO2013119040A1 Compounds as inhibitors of diacylglycerol o-acyltransferase type 1 enzyme |
| 08/15/2013 | WO2013118986A1 Triazolopyridine derivatives as a tyrosine kinase inhibitor |
| 08/15/2013 | WO2013118949A1 Phenyl derivatives or pharmaceutically acceptable salts thereof, method for preparing same, and composition comprising same as active ingredients for preventing, improving or treating diseases related to vascular endothelial cells or diabetes |
| 08/15/2013 | WO2013118136A1 Stable taurine oral composition |
| 08/15/2013 | WO2013118126A1 Ladostigil therapy for immunomodulation |
| 08/15/2013 | WO2013118102A1 Antiviral compounds with a heterotricycle moiety |
| 08/15/2013 | WO2013118097A1 Antiviral compounds with a dibenzooxaheterocycle moiety |
| 08/15/2013 | WO2013118077A1 2 - hydroxythymol diacetate and use thereof |
| 08/15/2013 | WO2013118071A1 BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS |
| 08/15/2013 | WO2013117986A1 Pyrroloquinoline alkaloids as antimalarial agents and process for the preparation thereof |
| 08/15/2013 | WO2013117969A1 Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis |
| 08/15/2013 | WO2013117963A1 Stable oral tablet dosage form of an antidiabetic compound |
| 08/15/2013 | WO2013117749A1 Pyrrolic derivatives, processes for preparing the same and their uses as a drug |
| 08/15/2013 | WO2013117744A2 Methods of treating fibrosis |
| 08/15/2013 | WO2013117735A1 Conjugate comprising an agent and an antiviral ligand and its use in a method for delivering the agent intracellularly |
| 08/15/2013 | WO2013117713A1 Reversal of senescence |
| 08/15/2013 | WO2013117693A1 Pde4 inhibitor for treating huntington's disease |
| 08/15/2013 | WO2013117683A1 New pediatric uses of cabazitaxel |
| 08/15/2013 | WO2013117649A1 Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |
| 08/15/2013 | WO2013117646A1 Novel compound useful for the treatment of degenerative and inflammatory diseases |
| 08/15/2013 | WO2013117645A1 Imidazo [4, 5 -c] pyridine derivatives useful for the treatment of degenerative and inflammatory diseases |
| 08/15/2013 | WO2013117615A1 Piperidino-pyrimidine derivatives for the treatment of viral infections |
| 08/15/2013 | WO2013117559A1 Thiamine derivatives and their use as antibiotics |
| 08/15/2013 | WO2013117522A1 Aurora and flt3 kinases modulators |
| 08/15/2013 | WO2013117512A1 Novel azetidine derivatives |
| 08/15/2013 | WO2013117504A1 Pi3k inhibitors for treating cough |
| 08/15/2013 | WO2013117503A2 Novel use |
| 08/15/2013 | WO2013117348A1 Agonists and antagonists of toll-like receptor (tlr) 13 |
| 08/15/2013 | WO2013117299A1 Deuterated thiazolidinone analogues as agonists for follicle stimulating hormone receptor |